VALIDATION OF QUALITY ASSESSMENT CRITERIA FOR PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES IN A VULNERABLE POPULATION: A WAY TO PERSONALIZED AUDIT
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Disabled people with cardiovascular diseases (CVD) are a vulnerable population for whom rational and safe pharmacotherapy is a critical component of medical and rehabilitation care. However, existing approaches to assessing the quality of drug therapy are often fragmented and do not take into account the complex medical and social characteristics of this patient group. The aim of the study was to create a standardized tool for pharmacotherapy audit. In the first stage, a primary pool of 17 criteria was formed, divided into two domains: 1) compliance with clinical guidelines (12 criteria) and 2) taking into account the individual characteristics of pharmacotherapy for disabled people (5 criteria). Validation was carried out using the expert consensus method with the participation of 23 highly qualified specialists in the field of medical and social expertise. The significance of each criterion was evaluated according to five parameters: clinical significance, the possibility of objective assessment, the impact on the quality and duration of life, the potential for improving the prognosis, and the applicability for dynamic monitoring. Based on the results of the expert assessment, a final system of 12 key criteria was formed. The criteria "Achieving the target level of LDL-C in IHD" (22,78 points) and "Monitoring the effectiveness of drug administration" (22,74 points) received the highest significance rating in the first domain. Among the criteria of the second domain, the highest priority was assigned to "The availability of an individual medical rehabilitation plan" (23,61 points). A comprehensive system of criteria has been developed and validated, integrating clinical, pharmacological, and medical-social aspects. Its implementation in practice will allow us to move from subjective assessment to a standardized audit of the quality of pharmacotherapy, promoting its personalization and improving its safety and effectiveness in disabled people with cardiovascular diseases.
Fields of Study & Subjects
Pharmaceutical Practices and Patient Outcomes
Medical and Pharmaceutic Studies
Pharmacy and Medical Practices
Publication details
- Journal / source
- Bulletin Biomedicine and sociology
- Volume
- 11
- Issue
- 01
- Pages
- 53–53
- Publication date
- 28 February 2026
- Language
- EN